Co-involvement of psychological and neurological abnormalities in infertility with polycystic ovarian syndrome

Archives of Gynecology and Obstetrics

Volumn 284, Issue 3, 2011, Pages 773-778

  Shi, Xiaobo ^a   Zhang, Lingyan ^a   Fu, Shuxin ^a   Li, Na ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Anxiety; Depression; Infertility; Neurotransmitter; Polycystic ovarian syndrome

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISTRESS SYNDROME; DOPAMINE BLOOD LEVEL; DOPAMINE METABOLISM; FEMALE; FEMALE INFERTILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSTILITY; HUMAN; MENTAL DISEASE; NEUROLOGIC DISEASE; NORADRENALIN BLOOD LEVEL; OBSESSIVE COMPULSIVE DISORDER; OVARY POLYCYSTIC DISEASE; PARANOIA; PHOBIA; PSYCHOSIS; SCORING SYSTEM; SEROTONIN BLOOD LEVEL; SEROTONIN METABOLISM; SOMATIZATION; SYMPTOM CHECKLIST 90; ANXIETY; BLOOD; CHECKLIST; PSYCHOLOGICAL ASPECT; SELF EVALUATION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANXIETY; CHECKLIST; DEPRESSION; DIAGNOSTIC SELF EVALUATION; DOPAMINE; FEMALE; HOMOVANILLIC ACID; HOSTILITY; HUMANS; HYDROXYINDOLEACETIC ACID; INFERTILITY, FEMALE; METHOXYHYDROXYPHENYLGLYCOL; NERVOUS SYSTEM DISEASES; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PHOBIC DISORDERS; POLYCYSTIC OVARY SYNDROME; SEROTONIN;

EID: 84856019188     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-011-1947-1     Document Type: Article

References (36)

1. Balen A, Michelmore K (2002) What is polycystic ovary syndrome? Are national views important? Hum Reprod 17:2219-2227 (Pubitemid 35021439)
2. Jones GL, Balen AH, Ledger WL (2008) Health-related quality of life in PCOS and related infertility: how can we assess this? Hum Fertil (Camb) 11:173-185
3. Doi SA, Towers PA, Scott CJ, Al-Shoumer KA (2005) PCOS: an ovarian disorder that leads to dysregulation in the hypothalamicpituitary-adrenal axis? Eur J Obstet Gynecol Reprod Biol 118:4-16 (Pubitemid 39647015)
4. Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8:41
5. Blank SK, Helm KD, McCartney CR, Marshall JC (2008) Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci 1135:76-84 (Pubitemid 351862121)
6. Legro RS, Castracane VD, Kauffman RP (2004) Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59:141-154 (Pubitemid 38140845)
7. Murdoch AP, Dunlop W, Kendall-Taylor P, Watson MJ (1984) The acute effects of a dopamine antagonist (domperidone) on luteinising hormone, follicule stimulating hormone, prolactin and thyrotrophin secretion in polycystic ovarian syndrome: differential effect of ovulation. Clin Endocrinol (Oxf) 21:611-619 (Pubitemid 15177588)
8. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM (2009) Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 94:2579-2586
9. Eyvazzadeh AD, Pennington KP, Pop-Busui R, Sowers M, Zubieta JK, Smith YR (2009) The role of the endogenous opioid system in polycystic ovary syndrome. Fertil Steril 92:1-12
10. Deeks AA, Gibson-Helm ME, Teede HJ (2010) Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril 93:2421-2423
11. Himelein MJ, Thatcher SS (2006) Polycystic ovary syndrome and mental health: a review. Obstet Gynecol Surv 61:723-732 (Pubitemid 44655530)
12. Elsenbruch S, Benson S, Hahn S, Tan S, Mann K, Pleger K, Kimmig R, Janssen OE (2006) Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod 21:1092-1099
13. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, Janssen OE (2003) Quality of life, psychosocial wellbeing, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:5801-5807 (Pubitemid 38033054)
14. Deeks AA, Gibson-Helm ME, Teede HJ (2010) Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril 93:2421-2423
15. Derogatis LR, Lipman RS, Covi L (1973) SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 9:13-28
16. McCook JG, Reame NE, Thatcher SS (2005) Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 34:12-20 (Pubitemid 40894689)
17. Coffey S, Mason H (2003) The effect of polycystic ovary syndrome on health related quality of life. Gynecol Endocrinol 17:379-386 (Pubitemid 37338868)
18. Dokras A, Clifton S, Futterweit W, Wild R (2011) Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol 117:145-152
19. Elsenbruch S, Hahn S, Kowalsky D et al (2003) Quality of life, psychosocial well being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:5801-5807 (Pubitemid 38033054)
20. Wang Y, Cao Y, Chong L et al (2005) Polycystic ovary syndrome and psychological analysis of the investigation. Anhui Med Univ (in Chinese) 40:277-279
21. Herbison AE (1997) Noradrenergic regulation of cyclic GnRH secretion. Rev Reprod 2:1-6 (Pubitemid 27165960)
22. Yoshino K, Takahashi K, Eda Y, Nishigaki A, Kitao M (1991) Peripheral catecholamine metabolites and free testosterone in patients with polycystic ovary syndrome. Nippon Sanka Fujinka Gakkai Zasshi 43:351-354
23. Barontini M, García-Rudaz MC, Veldhuis JD (2001) Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome. Arch Med Res 32:544-552 (Pubitemid 34031746)
24. Hernandez I, Parra A, Mendez I et al (2000) Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome. Arch Med Res 31:216-222 (Pubitemid 30392362)
25. Ramirez VD, Dluzen DE (1987) Release of luteinizing hormonereleasing hormone (LHRH) and neuroactive substances in unanesthetized animals as estimated with push-pull cannulae (PPC). Biol Reprod 36:59-76 (Pubitemid 17042069)
26. Wang J, Ouyang D, Ke J et al (2005) Neurotransmitter NA, 5-HT levels in hippocampus and content changes of GnRH in hypothalamus in female rats exposed to psychologic stress. Chinese J Gerontology (In Chinese) 25:673-674
27. Lobo RA, Granger LR, Paul WL et al (1983) Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. Am J Obstet Gynecol 145:496-503 (Pubitemid 13138140)
28. Gill SS, Pulido OM (2001) Glutamate receptors in peripheral tissues: current knowledge, future research, and implications for toxicology. Toxicol Pathol 29:208-223 (Pubitemid 32531621)
29. Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H (2002) GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol 213:1-47 (Pubitemid 34121040)
30. de Groat WC (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 147:S25-S40 (Pubitemid 43237573)
31. Roth BL, Chuang DM (1987) Multiple mechanisms of serotonergic signal transduction. Life Sci 41:1051-1064 (Pubitemid 17125222)
32. Hafkenscheid A (1993) Psychometric evaluation of the symptom checklist (SCL-90) in psychiatric inpatients. Pers Individ Differ 14:751-756
33. Clark A, Friedman MJ (1983) Factor structure and discriminant validity of the SCL-90 in a veteran psychiatric population. J Pers Assess 47:396-404 (Pubitemid 14236076)
34. Cyr JJ, McKenna-Foley JM, Peacock E (1985) Factor structure of the SCL-90-R: is there one? J Pers Assess 49:571-578
35. Grabill K, Merlo L, Duke D, Harford KL, Keeley ML, Geffken GR, Storch EA (2008) Assessment of obsessive-compulsive disorder: a review. J Anxiety Disord 22:1-17 (Pubitemid 350267129)
36. Ganellen RJ (2007) Assessing normal and abnormal personality functioning: strengths and weaknesses of self-report, observer, and performance-based methods. J Pers Assess 89:30-40 (Pubitemid 47237428)